Salignostics' Saliva-Based Pregnancy Test Receives TGA Approval, Set to Transform Australian Market
TL;DR
Salignostics' Salistick pregnancy test achieves TGA approval, positioning the company for expansion into the $2.1 billion global pregnancy test market.
Salistick's technology detects pregnancy hormone (β-hCG) in saliva, offering non-invasive, accurate, and user-friendly testing from home.
Salignostics' non-invasive pregnancy test provides accessible, accurate, and reliable testing options, aiming to make a lasting impact on healthcare worldwide.
Salistick's groundbreaking saliva-based technology transforms the testing experience, enabling easy, non-invasive pregnancy detection from the comfort of home.
Found this article helpful?
Share it with your network and spread the knowledge!
Salignostics, a pioneer in saliva-based diagnostic solutions, has achieved a significant milestone with the approval of its saliva-based pregnancy test, Salistick, by Australia's Therapeutic Goods Administration (TGA). This development opens doors for the company to introduce its innovative product to the Australian and New Zealand markets, potentially reshaping the landscape of home pregnancy testing.
The TGA approval, known for its stringent standards, validates the safety, quality, and efficacy of Salistick. This certification not only allows Salignostics to enter the Australian market but also positions the company for future regulatory approvals, including plans for U.S. FDA clearance in 2025. The approval comes after a year-long regulatory process and builds on Salistick's successful launches in the UK and Israel earlier in 2024.
Salistick's unique technology leverages saliva, which contains thousands of proteins similar to those found in blood, to detect the pregnancy hormone β-hCG. This non-invasive approach offers a more user-friendly alternative to traditional urine-based tests, potentially increasing accessibility and ease of use for consumers.
The implications of this approval are significant for both Salignostics and the broader home diagnostics market. With the Australian and New Zealand home pregnancy test market projected to reach $120 million by 2025, Salistick is well-positioned to capture a share of this growing sector. The global pregnancy test market, valued at approximately $2.1 billion in 2023, is expected to grow at a compound annual rate of 7% through 2030, indicating substantial potential for innovative products like Salistick.
Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics, emphasized the importance of this approval in the company's global expansion strategy. The success of Salistick, with over 500,000 units sold or ordered in its first year and availability in major pharmacy chains, demonstrates strong market demand for this innovative approach to pregnancy testing.
Beyond pregnancy testing, Salignostics is leveraging its saliva-based diagnostic technology for other applications, including COVID-19 testing and planned expansions into detecting streptococcus, sexually transmitted diseases, and cardiac risk indicators. This diversification suggests broader implications for the future of home diagnostics and preventive healthcare.
As Salignostics prepares to enter the Australian and New Zealand markets with its TGA-approved product, the company is poised to challenge traditional methods of home diagnostics. The success of Salistick could pave the way for more saliva-based tests, potentially transforming how consumers approach personal health monitoring and early disease detection.
Curated from News Direct
